Accuray (Accuray) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Accuray Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Accuray is: High Risk: High uncertainty.

Competitive Comparison of Accuray's Risk Assessment

For the Medical Devices subindustry, Accuray's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accuray's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Accuray's Risk Assessment falls into.

Accuray (NAS:ARAY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Accuray Risk Assessment Related Terms

Thank you for viewing the detailed overview of Accuray's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Accuray (Accuray) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

XEJ:Germany

Address

1240 Deming Way, Madison, WI, USA, 53717

Website

https://www.accuray.com

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Executives

Gina Corradetti	officer: VP, Corporate Controller	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz	officer: SVP Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew	officer: SVP and General Counsel	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke	officer: SVP, Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter	officer: SVP & Chief Commercial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine	officer: SVP, Chief Admin Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge	officer: Senior VP Global Operations	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill	director	VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green	officer: Chief Financial Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba	officer: VP, Chief Accounting Officer	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott	director	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine	officer: President & CEO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura	director	471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters	director
Shigeyuki Hamamatsu	officer: VP, Finance and CAO	1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043